NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Amid Rising Cases

With measles cases climbing across the United States and globally, NanoViricides, Inc. (NYSE American: NNVC) is advancing its lead antiviral candidate, NV-387, toward a Phase II clinical trial for the treatment of measles. The company is developing a protocol to evaluate NV-387's efficacy in measles patients and intends to submit it to the U.S. Food and Drug Administration (FDA) through the Investigational New Drug (IND) process.

NV-387 has already demonstrated strong in vivo activity against lethal measles infection in a humanized animal model, according to the company. It has also received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug Designation (RPDD) from the FDA for measles. The RPDD designation is particularly significant because it makes NanoViricides eligible to receive a Priority Review Voucher upon approval of a qualifying marketing application, provided all requirements are met. These designations underscore the unmet medical need and the potential of NV-387 to address a serious public health concern.

The urgency of developing effective measles treatments is highlighted by recent outbreaks. Measles is highly contagious and can lead to severe complications, especially in children. While vaccination remains the primary prevention strategy, there is no specific antiviral treatment for measles once infection occurs. NV-387 could fill this gap, offering a therapeutic option for those infected, particularly in outbreak settings or for immunocompromised individuals.

NanoViricides' platform technology is based on host-mimetic nanomedicine, which uses specially designed nanomaterials that mimic host cells to attract and neutralize viruses. This approach is broad-spectrum, meaning NV-387 has potential applications against multiple viral infections, including respiratory syncytial virus (RSV), COVID-19, influenza, and even poxviruses. The company is also exploring NV-387 for other indications, but measles is a current focus due to the rising case numbers and the absence of approved treatments.

The company's business model involves licensing technology from TheraCour Pharma, Inc. and developing drugs for specific viral targets. NanoViricides has a worldwide exclusive perpetual license to TheraCour's nanomedicine technology for several viruses, including measles. The company's lead drug candidate, NV-387, is also being developed for other respiratory viruses, and its other candidate, NV-HHV-1, targets shingles.

While the progress toward Phase II is encouraging, the company acknowledges the lengthy and capital-intensive nature of drug development. NanoViricides cannot project an exact date for filing an IND due to reliance on external collaborators and consultants. However, the company remains focused on advancing NV-387 into human clinical trials, with measles as a priority indication.

The potential commercial incentive from the RPDD designation is substantial. Priority Review Vouchers can be sold or transferred and have historically fetched significant prices, sometimes exceeding $100 million. This could provide much-needed funding for the company's broader pipeline. Additionally, ODD offers benefits such as tax credits for clinical trial costs and a seven-year marketing exclusivity period upon approval.

As measles outbreaks continue to challenge public health systems, the development of NV-387 represents a critical step toward providing a treatment option. The FDA's designations reflect the seriousness of the disease and the promise of NanoViricides' approach. With the company's commitment to advancing NV-387, there is hope that an effective measles treatment may soon be within reach.